TABLE 3.
Extraintestinal symptoms after resolution of SARS‐CoV‐2 infection according to the Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) questionnaire
| SARS‐CoV‐2 | p‐value | Adjusted risk ratio | p‐value | ||
|---|---|---|---|---|---|
| n (%) | (95% confidence interval) | ||||
| Positive | Negative | ||||
| SAGIS extraintestinal | |||||
| Headache | 33 (20.1%) | 61 (33.3%) | 0.017 | 0.68 (0.46; 1.0) | 0.05 |
| Back pain | 46 (28.0%) | 68 (37.2%) | 0.185 | 0.65 (0.47; 0.90) | 0.01 |
| Sleep disturbances | 63 (38.4%) | 59 (32.2%) | 0.483 | 1.23 (0.90; 1.68) | 0.19 |
| Chronic fatigue | 52 (31.7%) | 25 (13.7%) | <0.001 | 2.24 (1.48; 3.37) | <0.001 |
| Depression | 13 (7.9%) | 7 (3.8%) | 0.262 | 1.35 (0.53; 3.45) | 0.52 |
| Anxiety disorder | 30 (18.3%) | 30 (16.4%) | 0.745 | 0.88 (0.53; 1.48) | 0.64 |
Adjusted risk ratios were obtained from multiple Poisson regression models with robust variance containing the covariates sex, age, level of education, past surgery, chronic medications, smoking habits, and psychological comorbidity.